Healthcare providers often make dosing decisions without critical blood level information. Saladax Assays ensure rapid, accurate results, preventing the risks of suboptimal drug levels or toxicities.
At Saladax, we strongly advocate that every patient receive treatment designed to secure optimal therapeutic outcomes.
Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax’s proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians monitor and optimize patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com
Mark's strengths include significant board experience, having served on the Board of MDXHealth for five years, where he demonstrated strategic thinking and governance expertise. He is particularly adept at bringing new diagnostic products to market, focusing on oncology and psychiatric medicine. His commitment to innovation is evident through his instrumental role in developing novel tests.
With a global reach, Mark has successfully launched diagnostic tests in the US and internationally, showcasing his understanding of global markets. His proven track record in commercialization, innovation, and leadership makes him a highly accomplished executive and a valuable asset to any organization.
Before joining Think.Health Ventures, Mr. Kainzinger has been Chief Executive Officer (CEO) of Labor Berlin between 2011 and 2015, the joint diagnostic organization of the Charité – university medical center and the Vivantes Network for Health Group with more than 400 employees on 12 sites in Berlin. Labor Berlin currently is the largest hospital connected laboratory network in Europe – with more than 25,000 beds being served by its lab organization.
Prior to Labor Berlin, Mr. Kainzinger worked at Roland Berger Strategy Consultants, a top-level strategic consulting firm, serving hospital and pharmaceutical clients in Germany and Europe. He holds a master’s degree from the University of Munich (Dipl.-Kfm.) and a Ph.D. in health economics from the Charité – Universitätsmedizin Berlin.
David was a member of the UK Department of Transport expert panel that introduced drug-driving regulation. He is currently a member of the UK government’s Advisory Council on Misuse of Drugs.
Professor Taylor is the Editor-in-Chief of the journal Therapeutic Advances in Psychopharmacology.
Professor Taylor has been the lead author of the Maudsley Prescribing Guidelines since their inception in 1993. The Maudsley Prescribing Guidelines have sold over 300,000 copies in fourteen editions and twelve languages. David has also authored over 350 clinical papers in journals such as the Lancet, BMJ, British Journal of Psychiatry and Journal of Clinical Psychiatry. These papers have been cited over 15,000 times. Professor Taylor has written or edited seven other books and written over twenty book chapters.
sciences with extensive experience in laboratory diagnostics, medical
devices, and life sciences. He has held significant non-executive board
positions and provided consulting services in strategy, portfolio
development, and project management. His work spans Germany, the
United States, Austria, and Switzerland, where he has launched over 120
products and managed complex development projects.
Dr. Brusdeilins' core competencies include strong business acumen,
strategy development, mergers and acquisitions, organizational and
talent development, and general management. He has developed and
managed strategic partnerships worldwide, including in Switzerland, the
USA, Japan, Malaysia, Singapore, and China. His multilingual proficiency
in German (native) and English (fluent) has further facilitated his global
engagements.
During his time with Saladax, he advanced the company's position in
oncology and psychiatry drug management, developing proprietary
assays that improved patient outcomes and solidified Saladax’s
reputation in healthcare diagnostics. He has also been the founder of
Galen DiaConsult GmbH, Executive Vice President at Tecan Trading AG,
and Vice President of Research & Development at Ortho-Clinical
Diagnostics Inc.